Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT05949632 2025-08-03

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

5 enrolled

GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 2 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

67 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03826589 2025-06-11

ALARICE

Phase NA Completed

23 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1/2 Completed

23 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02535533 2025-05-20

SLM + Axitinib for Clear Cell RCC

Phase 1 Completed

46 enrolled

Genitourinary

Kidney Neoplasms

NCT02597322 2025-04-06

AXIPAN

Phase 2 Completed

21 enrolled

cT2a N0NxM0 Renal Tumor

NCT06889649 2025-03-21

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Phase 2 Recruiting

30 enrolled

Radiation Therapy

NCT05256472 2025-03-06

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

70 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

1,250 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Phase 2 Completed

13 enrolled

Recurrence

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

11 enrolled

Tumor-Agnostic

Neoplasms

NCT05904730 2024-12-30

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Phase 1 Completed

10 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00828919 2024-12-03

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Phase NA Completed

52 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT06211114 2024-11-26

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Phase 2 Recruiting

30 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

AXMUS-C

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NEOPAX

SAMURAI

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

CAPTUR

MK-3475A-C18

SPARCC

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

KEYNOTE-426

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Axitinib + Ipilimumab in Advanced Melanoma

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

PADRES

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

AXAGIST

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

JAVELIN Renal 101

ProTarget

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

ALARICE

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

SLM + Axitinib for Clear Cell RCC

AXIPAN

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

CARE1

NPC - AXEL Study : Axitinib-Avelumab

StrataPATH

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma